Document is current
Any future updates will be listed below
-
Authors
Leisman, Daniel E. http://orcid.org/0000-0001-9670-9425
Handisides, Damian R.
Chawla, Lakhmir S.
Albertson, Timothy E.
Busse, Laurence W.
Boldt, David W.
Deane, Adam M.
Gong, Michelle N.
Ham, Kealy R.
Khanna, Ashish K.
Ostermann, Marlies
McCurdy, Michael T.
Thompson, B. Taylor
Tumlin, James S.
Adams, Christopher D.
Hodges, Tony N.
Bellomo, Rinaldo
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02338843 at ClinicalTrials.govDocuments that mention this clinical trial
Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial
https://doi.org/10.1186/s13054-023-04446-1
FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults with Distributive Shock
https://doi.org/10.1007/s40256-018-0297-9
Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock
https://doi.org/10.1186/s13613-023-01227-5
- License Information
-
More Information
Article History
Received: 7 August 2023
Accepted: 10 December 2023
First Online: 16 December 2023
Declarations
:
: The trial was conducted in accordance with Good Clinical Practice guidelines, applicable local regulations, and Declaration of Helsinki principles. The respective independent institutional review boards reviewed the protocol, informed-consent form, and all other documents before study initiation.
: Not applicable.
: DEL, AMD, KRH, and RB declare no competing interests. DRH, CDA, and TNH are employees of Innoviva Specialty Therapeutics, of which La Jolla Pharmaceutical Company (LJPC) is a subsidiary. LSC declares that he was formerly an employee of LJPC. TEA received consulting fees from LJPC. LWB served on the Speaker’s Bureau for LJPC and received consulting fees from LJPC. DWB served on the Speaker’s Bureau for LJPC and received consulting fees from LJPC. MNG received NIH and CDC grants for research unrelated to this study, fees for serving on scientific advisory panel for Philips Healthcare and Endpoint for advice on AI and personalized approach to sepsis, and previously received funding from LJPC for the conduct of the Athos-3 trial. AKK served on the Speaker’s Bureau for LJPC, received consulting fees from LJPC, and received research grant funding from La Jolla Pharmaceutical Company for the ATHOS-3 study and through the Wake Forest Center for Hypertension and Vascular Research for RAAS in septic shock. MTM served on the Speaker’s Bureau for LJPC. MO declares that her institution received research funding from LJPC. BTT declares that during a portion of this research, the author had a financial interest in Direct Biologics, a developer and manufacturer of regenerative biologic products, including an investigational treatment of COVID-19 associated ARDS. These interests were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies. JTT received research grant support and institutional funding from LJPC.
